I'd like to see how effective bisantrene is for FTO as well. While it would be great for shareholder if affective, I'm worried if we were bought out early on, big pharma might drop research into FTO and it wouldn't be realised. As Dr T has said, smaller biotech companies are better at innovation than larger ones, the larger ones are better at getting approvals and seeing drugs through to commercialisation.
Oncology - Pharma Deals News, page-151
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |